GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Files An 8-K Regulation FD Disclosure
On November 5, 2019, Genocea Biosciences, Inc. issued a press release announcing the presentation of preclinical and clinical data demonstrating that ATLAS™ can identify relevant neoantigens and exclude inhibitory neoantigens that suppress anti-tumor immune responses at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place from November 6 – 10, 2019 in National Harbor, Maryland. A copy of the press release, dated November 5, 2019, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information contained in this Item 7.01 of this Current Report on Form 8-K, including the exhibits attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
GENOCEA BIOSCIENCES, INC. Exhibit
EX-99.1 2 gnca_sitcabstractspressrel.htm EXHIBIT 99.1 Exhibit Investor Contact:Dan Ferry617-430-7576daniel@lifesciadvisors.comGenocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC)Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapyConfirm positive GEN-009 clinical immunogenicity resultsCAMBRIDGE,…
To view the full exhibit click
EX-99.1 2 gnca_sitcabstractspressrel.htm EXHIBIT 99.1 Exhibit Investor Contact:Dan Ferry617-430-7576daniel@lifesciadvisors.comGenocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC)Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapyConfirm positive GEN-009 clinical immunogenicity resultsCAMBRIDGE,…
To view the full exhibit click
here
About GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA)
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment. It has one product candidate in Phase II clinical development: GEN-003, which is a therapeutic vaccine or immunotherapy for the treatment of genital herpes infections. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. The Company’s pipeline also includes GEN-005, which is under malaria prophylaxis, Epstein-Barr virus and immuno-oncology programs in research stage of development.